

Microbiome forum

19.10.2017

IMI Stakeholder Forum 2017

Crowne Plaza Le Palace , Klimt room

8:30 – 9:00

Registration & welcome coffee

9:00 – 9:05

Welcome

Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)

9:05 – 9:30

Opening keynote

Nicola Bedlington, Secretary-General, European Patients' Forum (EPF)

• PLENARY •
Ballroom

9:30 – 9:35

Breakout into parallel sessions, Klimt room

9:35 - 9:40

Introduction by **Hugh Laverty**, Head of Science Operations, IMI

9:40 – 10:10

Lecture | Human gut microbiome in health and disease

Dusko S. Ehrlich, Research Director Emeritus, INRA, French National Institute for Agricultural Research

10:10 – 10:30

Questions & answers

Regulatory challenges in the drug-food continuum

10:30 – 10:45

Yolanda Sanz, Professor of Research, Head of Microbial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology (IATA), National Research Council (CSIC), Spain; Member of the EFSA Panel on Dietetic Products, Nutrition and Allergies

10:45 – 11:00

Nino Mihokovic, Quality Specialist, European Medicines Agency (EMA)

11:00 – 11:20

Questions & answers, moderated by **Maria Beatriz Da Silva Lima**, Chair of the IMI Scientific Committee, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

11:20 – 11:50

Coffee break

11:50 – 12:50

Stakeholder discussion | The potential of collaborative research: accelerating breakthroughs and reducing fragmentation in microbiome research

Antoine Coutant, General Manager, Savencia Ingredients and Nutritional Solutions

Wulf Fischer-Knuppertz, CEO & Chairman, Biocrates Life Sciences

Marco Greco, President of the European Patients' Forum (EPF), Past Chairman of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA)

Dirk Hadrich, Scientific Officer, DG Research & Innovation, European Commission

Frank Møller Aarestrup, Professor, National Food Institute, Technical University of Denmark; Global Microbial Identifier

Kristof Van Emelen, CSO – Product Development, ProDigest

Vijay Yajnik, Medical Director, Clinical Science, GI TAU, Takeda

Chaired by **Hugh Laverty**, IMI

**Themes under consideration for potential microbiome topics under an IMI
Call for proposals**

12:50 – 13:20

Large longitudinal studies with open access to metadata

Stefan Scherer, VP & Head Early Development, Strategy and Innovation US
Oncology, Novartis

Questions & Answers

13:20 – 14:00

Lunch break

14:00 – 15:00

**Bio-informatics solutions for strain level identification and analysis of
hypothetical genes**

**Bio-banks of identifiable species with metadata, reference methods and
standards**

Alain Pluquet, Corporate VP, Chief Data Officer, bioMerieux

Questions & Answers

15:00 – 15:30

**Translational studies addressing microbiome causality in human health and
disease**

Graham Somers, IMI Portfolio Director, GSK

Questions & Answers

15:30 – 16:00

Coffee break

16:00 – 17:00

Stakeholder Forum 2017 conclusions | Plenary

Feedback from patient forum and microbiome forum

Elisabetta Vaudano, Principal Scientific Manager, IMI

Catherine Brett, External Relations Manager, IMI

Concluding remarks

Anders Olason, Honorary President, EPF & Pierre Meulien, IMI

17:00

End of the event

• PLENARY •
Ballroom